JP3611863B2 - 眼科用懸濁液の製造方法 - Google Patents

眼科用懸濁液の製造方法 Download PDF

Info

Publication number
JP3611863B2
JP3611863B2 JP52598698A JP52598698A JP3611863B2 JP 3611863 B2 JP3611863 B2 JP 3611863B2 JP 52598698 A JP52598698 A JP 52598698A JP 52598698 A JP52598698 A JP 52598698A JP 3611863 B2 JP3611863 B2 JP 3611863B2
Authority
JP
Japan
Prior art keywords
milling
slurry
polymer
producing
tetramethylbutyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP52598698A
Other languages
English (en)
Japanese (ja)
Other versions
JP2000501749A (ja
Inventor
アリ、ユースフ
ベック、ロバート・イー
スポート、レックス・シー
Original Assignee
アルコン ラボラトリーズ， インコーポレーテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アルコン ラボラトリーズ， インコーポレーテッド filed Critical アルコン ラボラトリーズ， インコーポレーテッド
Publication of JP2000501749A publication Critical patent/JP2000501749A/ja
Application granted granted Critical
Publication of JP3611863B2 publication Critical patent/JP3611863B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A61K31/77—Polymers containing oxygen of oxiranes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP52598698A 1996-12-11 1997-09-05 眼科用懸濁液の製造方法 Expired - Lifetime JP3611863B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US3282096P 1996-12-11 1996-12-11
US60/032,820 1996-12-11
US08/886,933 1997-07-02
US08/886,933 US6071904A (en) 1996-12-11 1997-07-02 Process for manufacturing ophthalmic suspensions
PCT/US1997/015727 WO1998025620A1 (en) 1996-12-11 1997-09-05 Process for manufacturing ophthalmic suspensions

Publications (2)

Publication Number Publication Date
JP2000501749A JP2000501749A (ja) 2000-02-15
JP3611863B2 true JP3611863B2 (ja) 2005-01-19

Family

ID=26708929

Family Applications (1)

Application Number Title Priority Date Filing Date
JP52598698A Expired - Lifetime JP3611863B2 (ja) 1996-12-11 1997-09-05 眼科用懸濁液の製造方法

Country Status (13)

Country Link
US (1) US6071904A (cg-RX-API-DMAC10.html)
EP (1) EP0941094B1 (cg-RX-API-DMAC10.html)
JP (1) JP3611863B2 (cg-RX-API-DMAC10.html)
AT (1) ATE209917T1 (cg-RX-API-DMAC10.html)
CA (1) CA2274680C (cg-RX-API-DMAC10.html)
DE (2) DE69708912T2 (cg-RX-API-DMAC10.html)
DK (1) DK0941094T3 (cg-RX-API-DMAC10.html)
ES (1) ES2169416T3 (cg-RX-API-DMAC10.html)
FR (1) FR09C0022I2 (cg-RX-API-DMAC10.html)
LU (1) LU91554I2 (cg-RX-API-DMAC10.html)
NL (1) NL300388I2 (cg-RX-API-DMAC10.html)
PT (1) PT941094E (cg-RX-API-DMAC10.html)
WO (1) WO1998025620A1 (cg-RX-API-DMAC10.html)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4602399A (en) * 1998-06-30 2000-01-24 Leo Pharmaceutical Products Ltd. A/S (Lovens Kemiske Fabrik Produktionsaktieselskab) Prolonged release ophthalmic compositions containing a fluoroquinolone
EP1393277B1 (en) 2001-05-21 2006-07-19 Alcon, Inc. USE OF NF-Kappa-B INHIBITORS TO TREAT DRY EYE DISORDERS
PL367287A1 (en) 2001-05-21 2005-02-21 Alcon, Inc. Use of proteasome inhibitors to treat dry eye disorders
PL367097A1 (en) * 2001-05-21 2005-02-21 Alcon, Inc. Method of treating dry eye disorders
US7112588B2 (en) * 2001-05-21 2006-09-26 Alcon, Inc. Use of proteasome inhibitors to treat dry eye disorders
US6872382B1 (en) 2001-05-21 2005-03-29 Alcon, Inc. Use of selective PDE IV inhibitors to treat dry eye disorders
TWI298257B (en) 2001-05-31 2008-07-01 Allergan Inc Hypotensive lipid and timolol compositions and methods of using same
US6645994B1 (en) 2001-06-01 2003-11-11 Alcon, Inc. Method of treating dry eye disorders
JP2005523295A (ja) * 2002-03-01 2005-08-04 ノバガリ、ファルマ、エスアー 難溶性薬剤の自己乳化型薬物送達システム
KR101059711B1 (ko) * 2003-01-21 2011-08-29 센주 세이야꾸 가부시키가이샤 2-아미노-3-(4-브로모벤조일)페닐아세트산 함유 수성액제
US7892483B2 (en) * 2004-03-12 2011-02-22 Cipla Limited Sterilization process
WO2008035246A2 (en) 2006-07-28 2008-03-27 Novagali Pharma Sa Compositions containing quaternary ammonium compounds
PT1891939E (pt) * 2006-07-28 2013-10-07 Novagali Pharma Sa Composições contendo compostos de amónio quaternário
TWI544927B (zh) 2008-03-17 2016-08-11 愛爾康研究有限公司 具有低濃度的表面活性劑以促進治療劑之生物可利用性的藥學組成物
TWI489997B (zh) 2009-06-19 2015-07-01 Alcon Res Ltd 含有硼酸－多元醇錯合物之水性藥學組成物
MX2012006401A (es) * 2009-12-03 2012-07-10 Lupin Ltd Proceso para preparar composiciones oftalmicas farmaceuticas.
EP2394637A1 (en) * 2010-05-21 2011-12-14 Zaklady Farmaceutyczne Polpharma SA Process for obtaining sterile brinzolamide suspensions
US9061034B2 (en) 2010-07-29 2015-06-23 Allergan, Inc. Preservative free bimatoprost and timolol solutions
PL2598118T3 (pl) 2010-07-29 2019-01-31 Allergan, Inc. Roztwory bimatoprost i tymolol bez środków konserwujących
WO2012053011A2 (en) 2010-10-18 2012-04-26 Usv Limited Ophthalmic compositions comprising brinzolamide
US20130065888A1 (en) 2011-08-15 2013-03-14 Biserka Cetina-Cizmek Ophthalmic formulations and processes for their preparation
EP2638909A1 (en) 2012-03-15 2013-09-18 Azad Pharmaceutical Ingredients AG Process for preparing sterile Brinzolamide
GR1007906B (el) * 2012-03-22 2013-05-30 Φαρματεν Αβεε, Οφθαλμικο φαρμακευτικο σκευασμα περιεχον ενα αναστολεα καρβονικης ανυδρασης και μεθοδος για την παρασκευη αυτου
HUE034356T2 (en) 2012-05-09 2018-02-28 Icrom Spa Preparation of sterile medical brinzolamide
US20150119386A1 (en) * 2012-05-21 2015-04-30 Aurobindo Pharma Limited Process for preparing opthalmic suspension of brinzolamide
WO2014057499A1 (en) 2012-10-11 2014-04-17 Indoco Remedies Limited A process for manufacturing sterile brinzolamide ophthalmic suspension
CN104721136A (zh) * 2013-02-21 2015-06-24 四川大学 一种布佐林胺眼用纳米混悬剂及其制备方法
US9801813B2 (en) * 2013-10-17 2017-10-31 Sentiss Pharma Private Limited Preservative-free ophthalmic pharmaceutical formulation
US9820991B2 (en) * 2013-11-08 2017-11-21 Sentiss Pharma Private Limited Pharmaceutical composition comprising brinzolamide
US10463674B2 (en) 2013-11-08 2019-11-05 Sentiss Pharma Private Limited Process for manufacturing sterile ophthalmic pharmaceutical suspensions
EP3096740B1 (en) 2014-01-24 2020-09-30 Sentiss Pharma Private Limited Pharmaceutical composition comprising brinzolamide
PL407710A1 (pl) * 2014-03-28 2015-10-12 Instytut Farmaceutyczny Sposób wytwarzania preparatu kropli do oczu w postaci zawiesiny zawierającej brynzolamid i preparat wytworzony tym sposobem
JP6279395B2 (ja) * 2014-05-01 2018-02-14 東亜薬品株式会社 ブリンゾラミド懸濁性点眼液組成物の製造方法
US11285163B2 (en) 2014-10-20 2022-03-29 Sentiss Pharma Private Limited Ophthalmic solution
TWI700085B (zh) 2015-06-22 2020-08-01 新源生物科技股份有限公司 酪胺酸激酶抑制劑之眼用調配物的用途
CN107582519A (zh) * 2017-06-01 2018-01-16 合肥远志医药科技开发有限公司 一种布林佐胺滴眼液制剂及其制备方法
GR1009419B (el) 2017-11-07 2018-12-14 Φαρματεν Αβεε Οφθαλμικο φαρμακευτικο σκευασμα που περιεχει εναν συνδυασμο βρινζολαμιδης και βριμονιδινης και μεθοδος για την παρασκευη αυτου
WO2019207380A1 (en) 2018-04-25 2019-10-31 Shilpa Medicare Limited Ophthalmic compositions of brinzolamide
GR1009616B (el) * 2018-07-20 2019-10-11 Φαρματεν Α.Β.Ε.Ε. Οφθαλμικο φαρμακευτικο σκευασμα που περιεχει βρινζολαμιδη και τιμολολη και μεθοδος παρασκευης αυτου
MX2021014477A (es) 2019-05-29 2022-01-06 Lupin Ltd Nanoemulsion gelificante in situ de brinzolamida.
US20220105101A1 (en) * 2020-10-05 2022-04-07 Somerset Therapeutics, Llc Efficient brinzolamide and brimonidine compositions
WO2024236599A1 (en) 2023-05-16 2024-11-21 Micro Labs Limited Ophthalmic solution of brinzolamide

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5378703A (en) * 1990-04-09 1995-01-03 Alcon Laboratories, Inc. Sulfonamides useful as carbonic anhydrase inhibitors
IL101537A (en) * 1991-04-17 1997-11-20 Merck & Co Inc OPHTHALMIC COMPOSITIONS COMPRISING COMBINATIONS OF A CARBONIC ANHYDRASE INHIBITOR AND A b-ADRENERGIC ANTAGONIST
AU677577B2 (en) * 1992-02-21 1997-05-01 Alcon Laboratories, Inc. Topical antiglaucoma compositions comprising carbonic anhydrase inhibitors and beta-blockers
US5362758A (en) * 1992-09-18 1994-11-08 Pfizer Inc. Ophthalmic piroxicam solution
US5346702A (en) * 1992-12-04 1994-09-13 Sterling Winthrop Inc. Use of non-ionic cloud point modifiers to minimize nanoparticle aggregation during sterilization
US5429824A (en) * 1992-12-15 1995-07-04 Eastman Kodak Company Use of tyloxapole as a nanoparticle stabilizer and dispersant
US5576016A (en) * 1993-05-18 1996-11-19 Pharmos Corporation Solid fat nanoemulsions as drug delivery vehicles
US5422116A (en) * 1994-02-18 1995-06-06 Ciba-Geigy Corporation Liquid ophthalmic sustained release delivery system

Also Published As

Publication number Publication date
ATE209917T1 (de) 2001-12-15
AU4183897A (en) 1998-07-03
US6071904A (en) 2000-06-06
FR09C0022I2 (cg-RX-API-DMAC10.html) 2010-06-11
AU718079B2 (en) 2000-04-06
DE69708912T2 (de) 2002-04-11
NL300388I1 (nl) 2009-07-01
JP2000501749A (ja) 2000-02-15
FR09C0022I1 (cg-RX-API-DMAC10.html) 2009-09-25
WO1998025620A1 (en) 1998-06-18
NL300388I2 (nl) 2010-02-01
PT941094E (pt) 2002-05-31
DE122009000016I1 (de) 2009-06-25
DK0941094T3 (da) 2002-01-07
EP0941094B1 (en) 2001-12-05
EP0941094A1 (en) 1999-09-15
HK1019704A1 (en) 2000-02-25
CA2274680A1 (en) 1998-06-18
LU91554I2 (fr) 2009-06-22
ES2169416T3 (es) 2002-07-01
DE69708912D1 (de) 2002-01-17
CA2274680C (en) 2003-11-18

Similar Documents

Publication Publication Date Title
JP3611863B2 (ja) 眼科用懸濁液の製造方法
US6066292A (en) Sterilization process for pharmaceutical suspensions
JP5558582B2 (ja) 眼科用医薬組成物の調製方法
CN1211125C (zh) 局部给药的盐酸奥洛他定制剂
KR101475965B1 (ko) 플루오로메토론을 함유하는 현탁형 점안제
WO2012053011A2 (en) Ophthalmic compositions comprising brinzolamide
CN1089837A (zh) 眼用制剂
CN111821261B (zh) 用于制备无菌眼用水性丙酸氟替卡松a型纳米晶体混悬液的方法
CN115484957B (zh) 用于治疗眼部状况的制剂
EP0531529B1 (en) Process for preparing aqueous suspension
AU718079C (en) Process for manufacturing ophthalmic suspensions
JP6279395B2 (ja) ブリンゾラミド懸濁性点眼液組成物の製造方法
WO1999001358A1 (en) Milling bottle for autoclaving of pharmaceutical suspensions
CN1063944C (zh) 眼用复方妥布霉素混悬液的制法
HK1019704B (en) Process for manufacturing ophthalmic suspensions containing brinzolamide
US20150119386A1 (en) Process for preparing opthalmic suspension of brinzolamide
CA2412575C (en) Improved process for manufacturing compositions containing ciprofloxacin and hydrocortisone
MXPA99001755A (en) Process for manufacturing ophthalmic suspensions
KR102912349B1 (ko) 눈의 상황을 치료하기 위한 제제
JP2021521240A (ja) ブリンゾラミドの眼科用組成物
CN1812794A (zh) 溶液药用组合物
CN117379435A (zh) 一种眼用制剂及其制备方法
HK40080964A (en) A formulation for treating ophthalmic conditions
MXPA00005307A (en) Novel sterilization process for pharmaceutical suspensions
HK1032546A (en) Novel sterilization process for pharmaceutical suspensions

Legal Events

Date Code Title Description
A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20040203

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20040506

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20040617

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20040727

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20040820

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20040921

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20041021

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20081029

Year of fee payment: 4

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20091029

Year of fee payment: 5

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20091029

Year of fee payment: 5

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20101029

Year of fee payment: 6

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20101029

Year of fee payment: 6

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20111029

Year of fee payment: 7

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20121029

Year of fee payment: 8

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20131029

Year of fee payment: 9

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

EXPY Cancellation because of completion of term